ANIP (ANI Pharmaceuticals, Inc.)
Insider Trading Activity
Every open-market purchase and sale reported by ANIP officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-27 | Henry O Gosebruch | Director | A | — | — |
| 2026-08-26 | Nikhil Lalwani | PRESIDENT & CEO | Sell | — | — |
| 2026-08-13 | Meredith Cook | SR. VP, GENERAL COUNSEL & SEC. | Sell | — | — |
| 2026-08-11 | Ori Gutwerg | SVP, GENERICS | Sell | — | — |
| 2026-07-30 | STEPHEN P. CAREY | SVP & CFO | Sell | — | — |
| 2026-07-21 | Meredith Cook | SR. VP, GENERAL COUNSEL & SEC. | F | — | — |
| 2026-07-14 | Meredith Cook | SR. VP, GENERAL COUNSEL & SEC. | Sell | — | — |
| 2026-07-06 | STEPHEN P. CAREY | SVP & CFO | MIXED | — | — |
| 2026-06-15 | Meredith Cook | SR. VP, GENERAL COUNSEL & SEC. | Sell | — | — |
| 2026-06-10 | Jeanne Thoma | Director | A | — | — |
| 2026-06-10 | Matthew J Leonard | Director | A | — | — |
| 2026-06-10 | Antonio R Pera | Director | A | — | — |
| 2026-06-10 | THOMAS HAUGHEY | Director | MIXED | — | — |
| 2026-06-10 | RENEE P TANNENBAUM | Director | A | — | — |
| 2026-06-09 | STEPHEN P. CAREY | SVP & CFO | MIXED | — | — |
| 2026-05-13 | Nikhil Lalwani | PRESIDENT & CEO | Sell | — | — |
| 2026-05-13 | Meredith Cook | SR. VP, GENERAL COUNSEL & SEC. | Sell | — | — |
| 2026-05-13 | Patrick D Walsh | Director | Sell | — | — |
| 2026-05-13 | Ori Gutwerg | SVP, GENERICS | Sell | — | — |
| 2026-05-13 | Thomas Andrew Rowland | SVP, HEAD - ESTABLISHED BRANDS | Sell | — | — |
| 2026-04-13 | Meredith Cook | SR. VP, GENERAL COUNSEL & SEC. | Sell | — | — |
| 2026-03-13 | Christopher Mutz | HEAD OF RARE DISEASE | Sell | — | — |
| 2026-03-13 | Thomas Andrew Rowland | SVP, HEAD - ESTABLISHED BRANDS | Sell | — | — |
| 2026-03-13 | Meredith Cook | SR. VP, GENERAL COUNSEL & SEC. | Sell | — | — |
| 2026-03-10 | STEPHEN P. CAREY | SVP & CFO | F | — | — |
| 2026-03-10 | Ori Gutwerg | SVP, GENERICS | F | — | — |
| 2026-03-10 | Nikhil Lalwani | PRESIDENT & CEO | F | — | — |
| 2026-03-10 | Krista Davis | SVP, CHIEF HR OFFICER | Sell | — | — |
| 2026-03-10 | Christopher Mutz | HEAD OF RARE DISEASE | MIXED | — | — |
| 2026-03-05 | STEPHEN P. CAREY | SVP & CFO | MIXED | — | — |
| 2026-03-04 | Christopher Mutz | HEAD OF RARE DISEASE | Sell | — | — |
| 2026-03-04 | Ori Gutwerg | SVP, GENERICS | Sell | — | — |
| 2026-03-03 | Patrick D Walsh | Director | Sell | — | — |
| 2026-03-02 | Christopher Mutz | HEAD OF RARE DISEASE | MIXED | — | — |
| 2026-03-02 | Ori Gutwerg | SVP, GENERICS | MIXED | — | — |
| 2026-03-02 | Nikhil Lalwani | PRESIDENT & CEO | MIXED | — | — |
| 2026-03-02 | STEPHEN P. CAREY | SVP & CFO | MIXED | — | — |
| 2026-03-02 | Muthusamy Shanmugam | HEAD OF R&D, COO-NOVITIUM OPS | A | — | — |
| 2026-03-02 | Thomas Andrew Rowland | SVP, HEAD - ESTABLISHED BRANDS | MIXED | — | — |
| 2026-03-02 | Chad Gassert | SVP - CORP. DEV. & STRATEGY | MIXED | — | — |
| 2026-03-02 | Meredith Cook | SR. VP, GENERAL COUNSEL & SEC. | MIXED | — | — |
| 2026-03-02 | Krista Davis | SVP, CHIEF HR OFFICER | MIXED | — | — |
| 2026-02-23 | Krista Davis | SVP, CHIEF HR OFFICER | Sell | — | — |
| 2026-02-23 | Christopher Mutz | HEAD OF RARE DISEASE | Sell | — | — |
| 2026-02-17 | Thomas Andrew Rowland | SVP, HEAD - ESTABLISHED BRANDS | F | — | — |
| 2026-02-17 | STEPHEN P. CAREY | SVP & CFO | F | — | — |
| 2026-02-17 | Ori Gutwerg | SVP, GENERICS | F | — | — |
| 2026-02-17 | Meredith Cook | SR. VP, GENERAL COUNSEL & SEC. | MIXED | — | — |
| 2026-02-17 | Christopher Mutz | HEAD OF RARE DISEASE | MIXED | — | — |
| 2026-02-17 | Krista Davis | SVP, CHIEF HR OFFICER | F | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 2,671,481 | — |
| — | 10%+ Owner | 2,350,559 | — |
| — | Director | 2,019,259 | — |
| — | 10%+ Owner | 1,819,259 | — |
| — | HEAD OF R&D, COO-NOVITIUM OPS | 532,976 | — |
| — | PRESIDENT & CEO | 344,489 | — |
| — | Director | 334,292 | — |
| — | SVP - CORP. DEV. & STRATEGY | 233,406 | — |
| — | President and CEO | 192,424 | — |
| — | SVP & CFO | 174,693 | — |
| — | SVP OPS & PROD DEV | 117,829 | — |
| — | HEAD OF RARE DISEASE | 91,309 | — |
| — | SVP - NEW BUS DEV & SPEC SALES | 87,477 | — |
| — | SVP, GENERICS | 75,534 | — |
| — | SR. VP, GENERAL COUNSEL & SEC. | 74,424 | — |
| — | SVP, CHIEF HR OFFICER | 57,033 | — |
| — | Vice President and CFO | 54,298 | — |
| — | Director | 48,432 | — |
| — | Director | 45,464 | — |
| — | Director | 40,878 | — |
| — | Director | 38,561 | — |
| — | SVP, HEAD - ESTABLISHED BRANDS | 38,271 | — |
| — | Director | 29,514 | — |
| — | Director | 27,762 | — |
| — | Director | 27,017 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the ANIP quote page; the site-wide leaderboard is on the insider transactions hub.